Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > BUSINESS
BUSINESS
- Ayumi Taps Kiyonori Karasawa as New Chief
June 28, 2019
- Takeda CEO Takes Home 1.75 Billion Yen in FY2018
June 28, 2019
- Japan OKs Companion Diagnostic for Rozlytrek: Chugai
June 28, 2019
- Takeda Shareholders Block Old Guard Group’s Claw-Back Pitch
June 28, 2019
- Takeda Vows 4.6 Billion Yen Commitment to Support Disease Prevention in Developing and Emerging Nations
June 27, 2019
- Ono Grabs Rights to US Biotech’s Metabolic Cancer Drug
June 26, 2019
- Poxel/Sumitomo’s Imeglimin Delivers Again, This Time in Insulin Combo Study
June 26, 2019
- Daiichi Sankyo to Return Rights to 4 Diagnostic Imaging Agents to GE Healthcare
June 26, 2019
- Opdivo Shows No Significant Difference vs Sorafenib in OS for 1st-Line HCC Use in Global PIII: BMS
June 26, 2019
- MSD’s Zerbaxa Now Available in Japan 4 Months after NHI Price Listing; Ensuring Stable Supply
June 26, 2019
- Days after Japan OK, FDA Spurns Daiichi Sankyo’s Quizartinib
June 25, 2019
- Shionogi Hooks Up with Ferrer to Promote Rizmoic in Spain
June 25, 2019
- Shionogi Licenses Mulpleta, Epertinib to China’s Eddingpharm Group
June 25, 2019
- 2018 Global Pharma Market Valued at US$1.09 Trillion, Humira Resounding No. 1: IQVIA
June 24, 2019
- ViiV Supporting Campaigns to Raise HIV Diagnosis Rate in Japan: CEO
June 24, 2019
- Ex-Otsuka Kagaku Exec Becomes PeptiStar’s New President
June 24, 2019
- Lantus/Lyxumia Combo Shows Effectiveness in Japan PIII: Sanofi
June 21, 2019
- Royalty Feud with Nobel Laureate Takes Center Stage at Ono Shareholder Meeting
June 21, 2019
- Japan IBD Market Projected at 155.8 Billion Yen in 2027: Fuji Keizai
June 20, 2019
- Fujifilm to Invest 300 Million Yen in Shimane Univ. Spinoff Regenerative Medicine Biotech
June 20, 2019
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…